CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
急性髓系白血病免疫治疗展望：当前进展与挑战
英文原题：A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges.
查看英文原题
A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
过去十年，急性髓系白血病（AML）的潜在致病机制得到广泛研究，人们对该病的认识显著加深。然而，化疗耐药和疾病复发仍是治疗成功的主要障碍。传统细胞毒性化疗常伴急性和慢性不良反应，尤其不适用于老年患者的巩固化疗，因此越来越多研究致力于解决这一问题。近期已开发多种 AML 免疫疗法，包括免疫检查点抑制剂、单克隆抗体、树突状细胞（DC）疫苗，以及基于工程化抗原受体的 T 细胞疗法。本综述介绍 AML 免疫治疗的近期进展，并讨论最有潜力的有效疗法和主要挑战。
展开英文摘要原文
During the last decade, the underlying pathogenic mechanisms of acute myeloid leukemia (AML) have been the subject of extensive study which has considerably increased our understanding of the disease.
However, both resistance to chemotherapy and disease relapse remain the principal obstacles to successful treatment. Because of acute and chronic undesirable effects frequently associated with conventional cytotoxic chemotherapy, consolidation chemotherapy is not feasible, especially for elderly patients, which has attracted a growing body of research to attempt to tackle this problem.
Immunotherapies for acute myeloid leukemia, including immune checkpoint inhibitors, monoclonal antibodies, dendritic cell (DC) vaccines, together with T-cell therapy based on engineered antigen receptor have been developed recently.
Our review presents the recent progress in immunotherapy for the treatment of AML and discusses effective therapies that have the most potential and major challenges.
论文信息
- 作者
- Chen Y、Wang J、Zhang F、Liu P
- 单位
- Department of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.China
- 文献类型
- 综述
- 期刊
- Frontiers in pharmacology2023
- 原文标识
- PubMed 37153761 · DOI 10.3389/fphar.2023.1151032
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →